Prescribing information

 

A short video explaining how to prepare and administer the Beovu pre-filled syringe.

 

References

  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, December 2021.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, November 2021.
  3. Beovu Patient Information leaflet, 2020.

 

AMD, age-related macular degeneration; HCP, healthcare professional.

Rate this content: 
No votes yet
UK | December 2021 | 178952
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]